期刊文献+

乳腺癌的内科治疗进展 被引量:1

原文传递
导出
摘要 乳腺癌在全世界妇女中是第一位的恶性肿瘤,每年约有7.9万新病例,占全部女性恶性肿瘤总数21%。全世界乳腺癌年均发病率为30.30/10万。美国癌症协会估计,2002年在美国确诊的乳腺癌新发病例大约为20.5万,大约有4万患者死于该病,是美国妇女最常见的恶性肿瘤,在女性癌症死因中仅次于肺癌。目前我国尚缺乏全国性乳腺癌发病统计资料。从全国死亡抽样调查的资料中可见,1990年至1992年期间,我国女性乳腺癌死亡率为3.38/10万,世调率为3.75/10万,在女性恶性肿瘤死亡中居第6位。
作者 杨迅 陈奇勋
出处 《中国基层医药》 CAS 2008年第11期1905-1906,共2页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献8

  • 1Citron ML,Berry DA,Cirrincione C ,et al. Randomized trial of dose dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol,2003,21 (8) :1431-1439.
  • 2Sparano JA,Wang M ,Martino S,et al. Phase Ⅲ study of doxorubicin eyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axil/ary node positive orhigh risk node negative breast cancer:results of North American Breast Cancer Intergroup Trial E1199. Breast Cancer Res Treat, 2005 ( Suppl 1 ). Latebreaking Abstract 48.
  • 3Steger GG, Galid A, Gnant M, et al. Pathologic complete reponse with six compared with three cycles of neoadjuvant cpirubicin plus docetaxel and granulocyte colonystimulating factor in operable breast cancer: result of ABCSG14. J Clin Oncol,2007,25 (15) : 2012-2018.
  • 4ATAC Tfialists Group. Result of the ATAC( Arimidcx,Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet ,2005,365 (94537) :60-62.
  • 5Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine responsive early breast cancer: update of study BIG 1-98. J Clin Oncol,2007,25 (5) :486-492.
  • 6Forbes JF, Kennedy J, Pienkowski T, et al. BCIRG 007 : randomized phase Ⅲ trial of trastuzumab plus docetaxel with or withoutearbop latin first line in HER2 positive metastatic breast cancer(MBC). J Clin Oncol,2006,24,18S(Suppl) : LBAS16.
  • 7Mackey JR, Kaufman B, Clemens M. Trastuzumab prolongs progression free survival in hormone dependent and HER2 positive meta- static breast cancer. Breast Cancer Res Treat,2006, 110 (Suppl 1) :S5.
  • 8Miller K,Wang M,Gralow J,et al. A randomized phase Ⅲ trial of paclitaxel versus paclitaxel plus bevaeizumab as first line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oneology Group(E2100). Breast Cancer Res Treat ,2005,94 ( Suppl 1 ) : S6.

同被引文献4

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部